Results 11 to 20 of about 15,096 (180)

Single versus repeated intravenous oncolytic reovirus infusions: Implications for immune modulation and rationalised scheduling of therapy in hepatocellular carcinoma [PDF]

International Journal of Cancer, Volume 158, Issue 12, Page 3252-3267, 15 June 2026.
What's new? Oncolytic viruses are a promising immunotherapeutic approach against many malignancies. However, it is unclear whether repeated doses have improved therapeutic value or may trigger greater side effects, especially in patients with hepatocellular carcinoma whose liver is chronically damaged.
Karen J. Scott, Emma J. West, Rebecca J. Brownlie, Fay Ismail, Christy Ralph, Thomas Heineman, Matt Coffey, Alan A. Melcher, Alison Taylor, Salvatore Papa, Adel Samson   +10 more
wiley   +2 more sources

Ataxin-2-like promotes translation of nonpolyadenylated reovirus mRNA [PDF]

Nature Communications
Mammalian orthoreovirus (reovirus) nonstructural protein μNS nucleates viral factories (VFs), which are sites of viral genome replication, protein synthesis, and particle assembly.
Xayathed Somoulay, Gavin S. Treadaway, Stefanie Hedayati, Myles E. Steed, Nathan E. Adam, Monico S. Williams, John S. L. Parker, John L. Woolford, Laurie A. Silva, Gwen M. Taylor, Terence S. Dermody   +10 more
doaj   +2 more sources

Reovirus resistance in tumors mediated by elevated ISG expression: overcoming therapeutic resistance via JAK/STAT pathway modulation [PDF]

Virology Journal
Background Oncolytic viruses such as reovirus hold significant promise for cancer therapy, but their efficacy varies across tumor types due to heterogeneous tumor cell sensitivity to reovirus.
Yuxin Yang, Xiaojin Lin, Liang Chen, Yuting Fan, Xiaowei Dou, Jing Zhang, Yingchun Zhang, Dan Liang, Xing Zhao   +8 more
doaj   +2 more sources

Oncolytic Therapy: Delivery System and New Therapeutic Strategies for Cancer [PDF]

MedComm, Volume 7, Issue 4, April 2026.
This review summarizes recent advances in nanoparticle‐ and cell‐mediated OVs delivery strategies that improve biodistribution and tumor targeting while limiting immune clearance. It also examines combination approaches that enhance therapeutic efficacy through tumor microenvironment modulation or immune activation, thereby overcoming immunosuppression
Sikan Jin, Yi Zhang, Ziling Zhou, Yaqi Zhang, Ting Yu, Rui Xu, Lin Xu, Jidong Zhang, Longze Zhang, Shan Yang, Xianyao Wang   +10 more
wiley   +2 more sources

PUMA and NF-kB Are Cell Signaling Predictors of Reovirus Oncolysis of Breast Cancer. [PDF]

PLoS ONE, 2017
Reovirus is a ubiquitous RNA virus that exploits aberrant signaling pathways for its replication. The oncolytic potential of reovirus against numerous cancers under pre-clinical/clinical conditions has been documented by us and others. Despite its proven
Chandini Thirukkumaran, Zhong-Qiao Shi, Ponnampalam Thirukkumaran, Joanne Luider, Karen Kopciuk, Jason Spurrell, Kate Elzinga, Don Morris   +7 more
doaj   +1 more source

Mutagenic specificity in reovirus [PDF]

Journal of Virology, 1979
Mutagenic specificity in response to chemical mutagens has been observed with certain temperature-sensitive mutants of reovirus type 3. One mutant induced by nitrous acid reverted specifically with nitrous acid. Three nitrosoguanidine-induced mutants reverted after nitrous acid treatment.
U R, Ray, B N, Fields
openaire   +2 more sources

Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche

Journal for ImmunoTherapy of Cancer, 2021
Background Multiple myeloma (MM) remains an incurable disease and oncolytic viruses offer a well-tolerated addition to the therapeutic arsenal. Oncolytic reovirus has progressed to phase I clinical trials and its direct lytic potential has been ...
Victoria Jennings, Christopher Parrish, Christy Ralph, Alan Melcher, Adel Samson, Gordon Cook, Fiona Errington-Mais, Matt Coffey, Munitta Muthana, Gemma Migneco, Louise M E Müller, Gina B Scott, Jenny Down, Sancha King, Basem Askar, Babatunde Oyajobi, Karen Scott, Emma West, Elizabeth J Ilett, Michelle Lawson   +19 more
doaj   +1 more source

Cytokine-induced killer cell delivery enhances the antitumor activity of oncolytic reovirus. [PDF]

PLoS ONE, 2017
Oncolytic viruses (OV) have recently emerged as a promising therapeutic modality in cancer treatment. OV selectively infect and kill tumor cells, while sparing untransformed cells.
Xing Zhao, Weiwei Ouyang, Cariad Chester, Shiqi Long, Nianxue Wang, Zhixu He   +5 more
doaj   +1 more source

Defective Virions of Reovirus [PDF]

Journal of Virology, 1970
When purified preparations of stock reovirus, type 3, were digested with chymotrypsin, the virions were converted into two different types of particle. These new particles could be separated from each other by isopycnic centrifugation in cesium chloride gradients. One particle banded at a buoyant density of 1.43 g/cm 3
M, Nonoyama, Y, Watanabe, A F, Graham
openaire   +2 more sources

Glycan Engagement Dictates Hydrocephalus Induction by Serotype 1 Reovirus

mBio, 2015
Receptors expressed on the host cell surface adhere viruses to target cells and serve as determinants of viral tropism. Several viruses bind cell surface glycans to facilitate entry, but the contribution of specific glycan moieties to viral disease is ...
Jennifer Stencel-Baerenwald, Kerstin Reiss, Bärbel S. Blaum, Daniel Colvin, Xiao-Nan Li, Ty Abel, Kelli Boyd, Thilo Stehle, Terence S. Dermody   +8 more
doaj   +1 more source